FDA Approves CABENUVA Once-Monthly Treatment For HIV

The U.S. Food and Drug Administration (FDA) approved CABENUVA (rilpivirine and cabotegravir), the first long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression. CABENUVA consists of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir. In the U.S., ViiV Healthcare is the marketing authorization holder for CABENUVA.

CABENUVA comes as a co-packaged kit with two injectable medicines. CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the . . .